Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study evaluates the efficacy and safety of single dose preoperative ferric
carboxymaltose in the prevention of postoperative infections and blood transfusions in
patients scheduled for cardiac surgery. Half of the patients will receive ferric
carboxymaltose and half of the patients physiological saline solution as placebo.